“Safety and Tolerability of Tirbanibulin 1% Treatment of Actinic Keratosis on Face and Scalp in Routine Clinical Practice Across the U.S. (PROAK Study)” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s263. doi:10.25251/skin.7.supp.263.